Li Qiuyu, Liu Lu, Yin Wenjie, Zhu Zhuo, Xu Hong
Department of Intensive Care Unit, Kunming Medical University Affiliated Yan'an Hospital Kunming 650051, Yunnan, China.
Department of Pharmacy, Kunming Medical University Affiliated Yan'an Hospital Kunming 650051, Yunnan, China.
Am J Transl Res. 2024 Nov 15;16(11):6626-6635. doi: 10.62347/VUAI5958. eCollection 2024.
This systematic review and meta-analysis aims to evaluate the efficacy and safety of safflower yellow (SY) combined with low molecular weight heparin (LMWH) in preventing deep vein thrombosis (DVT) after orthopedic surgery.
We conducted a comprehensive investigation of PubMed, EMbase, Cochrane Library, CNKI, VIP, and Wanfang databases to identify randomized controlled trials (RCTs) from January 2000 to March 2024. These trials compared the efficacy of SY combined with LMWH versus LMWH alone in preventing post-surgical DVT. Primary outcomes were the incidence of DVT, activated partial thromboplastin time (APTT), and prothrombin time (PT). The methodological quality of included studies was assessed using the modified Jadad scale. The meta-analysis, conducted with using RevMan 5.3 and STATA, employed fixed or random-effects models depending on heterogeneity assessments. It calculated risk ratios (RR) for DVT incidence and mean differences for APTT/PT, while also evaluating robustness and publication bias. Significance thresholds were set at P < 0.05 and P < 0.1, respectively.
Our analysis included eight RCTs involving 624 patients. The meta-analysis revealed that the combination of SY and LMWH significantly reduced the incidence of DVT (RR: 0.29, 95% CI: 0.16-0.52) compared to LMWH alone, with no difference in adverse reaction rate. Additionally, the combination therapy demonstrated improved APTT and PT profiles.
The combination of SY and LMWH is more effective than LMWH alone for preventing DVT post orthopedic surgery, offering a promising alternative for thromboprophylaxis in these patients.
本系统评价和荟萃分析旨在评估红花黄色素(SY)联合低分子肝素(LMWH)预防骨科手术后深静脉血栓形成(DVT)的有效性和安全性。
我们对PubMed、EMbase、Cochrane图书馆、中国知网、维普和万方数据库进行了全面检索,以识别2000年1月至2024年3月期间的随机对照试验(RCT)。这些试验比较了SY联合LMWH与单独使用LMWH预防术后DVT的疗效。主要结局指标为DVT发生率、活化部分凝血活酶时间(APTT)和凝血酶原时间(PT)。采用改良Jadad量表评估纳入研究的方法学质量。使用RevMan 5.3和STATA进行荟萃分析,根据异质性评估采用固定效应或随机效应模型。计算DVT发生率的风险比(RR)和APTT/PT的均值差,同时评估稳健性和发表偏倚。显著性阈值分别设定为P<0.05和P<0.1。
我们的分析纳入了8项RCT,涉及624例患者。荟萃分析显示,与单独使用LMWH相比,SY联合LMWH显著降低了DVT的发生率(RR:0.29,95%CI:0.16-0.52),不良反应发生率无差异。此外,联合治疗显示APTT和PT指标有所改善。
SY联合LMWH在预防骨科手术后DVT方面比单独使用LMWH更有效,为这些患者的血栓预防提供了一种有前景的替代方案。